Roche Boasts Of Tecentriq's Broad Potential In 3Q Earnings Update
Executive Summary
Roche CEO Severin Schwan called recently launched PD-L1 drug Tecentriq's CHF77m sales figure impressive when presenting the company's third-quarter earnings on Oct. 20. Roche also spotlighted its "comprehensive" immuno-oncology portfolio which is producing "quantity as well as quality" with five product launches in 12 months.
You may also be interested in...
Bristol Still Rules Immuno-Oncology, But For How Long?
At $920m, sales for Opdivo still overshadow competitors, but market dynamics are set to change with introduction of Merck's Keytruda in first-line lung cancer and Roche's Tecentriq in second-line lung.
Keytruda, Opdivo Set To Challenge Tecentriq In Bladder Cancer
Phase III trial of Merck's Keytruda stops early with survival benefit as FDA accepts filing of Bristol's Opdivo, which has breakthrough therapy status and priority review.
Roche: OAK Data Differentiates Tecentriq In Second-Line Lung Cancer
ESMO data suggest that patients with no expression of PD-L1 who took Tecentriq were able to generate an immune response, a result Genentech believes reflects the particular mechanism of action compared to PD-1 inhibitors like Opdivo and Keytruda.